Abstract
Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.
Highlights
MethodsCoronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
While dexamethasone treatment reduced mortality in severe and critical COVID-19, and remdesivir treatment was associated with shortening the recovery time in hospitalized patients, additional therapy approaches are urgently needed [1, 2]
The use of monoclonal SARS-CoV-2 spike antibodies, bamlanivimab (LY-CoV555), has been associated with a decrease in hospitalization frequency in outpatients with COVID-19 [3]; a recent report showed no significant efficacy of LY-CoV555 administration in hospitalized patients [4], possibly due to the recruitment of symptomatic patients at the later stage of disease progression and the increasing prevalence of escape mutations [5, 6]
Summary
MethodsCoronavirus disease (COVID-19) is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The administration of mABs was possible for patients at risk of severe or critical COVID-19, initially available for hospitalized patients only within a national emergency program.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
